Abstract: A method of suturing a trocar path incision in a tissue of a patient with an obturator includes inserting the obturator through the tissue such that a shaft of the obturator extends through a tissue opening about the trocar path incision and a distal tip of the obturator is positioned within a cavity of the patient. The method also includes directing the suture via a suturing feature with the obturator inserted through the tissue in order to direct the suture relative to the tissue. Furthermore, the method includes closing the tissue opening about the trocar path incision with the suture.

Abstract: An article of manufacture, such as a weighted blanket, a cushioning element, or the like, includes an elastomeric element that includes elongated elements that follow nonlinear, partially overlapping paths and voids between adjacent portions of the elongated elements. Such an elastomeric element may define a weighted layer of a weighted blanket, a cushioning layer of a cushioning element of the like. The elastomeric element may be secured directly to a substrate, such as a fabric layer. Alternatively, an adhesion layer may secure the elastomeric element to the substrate. An adhesion layer may cover only a portion of the substrate. A cover may be provided over the elastomeric element. Together, the cover and the substrate may contain the elastomeric element.

Abstract: This invention relates to a process for the preparation of a silica-treated functionalized resin composition comprising the steps of reacting a polymer backbone with a hydrosilylation agent to produce a silane-functionalized resin composition, wherein the polymer backbone is selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof; and mixing the silane-functionalized resin composition with a silica to produce a silica-treated functionalized resin composition.

Abstract: This invention relates to a process for the preparation of a silane-functionalized resin composition comprising the steps of mixing a polymer backbone, a silane, and a free radical initiator; and producing a silane-functionalized resin composition. The polymer backbone is selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof.

Abstract: This invention relates to a functionalized resin composition having the formula P—S—X where S is a spacer selected from at least one of C2-C40 straight chain and branched alkyl, C6-C40 aromatics, butadiene, isoprene, and combinations thereof, P is a polymer backbone selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof, and X is a silane.

Abstract: An ethylene copolymer, a Group 4 transition metal catalyst compound, and methods for polymerization using such a compound, said compound represented by the formula: (L)p(R?)zT(Cp)(A)MX2, where M is a Group 4 metal; z is 0 to 8; p is 1 to 3; X is an anionic leaving group; T is a bridging group; R1 to R4 are hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group, aryl group, substituted aryl group, or a heteroatom-containing group (where adjacent R groups can form rings); R? is hydrogen, a C1 to C10 alkyl group, a C6 to C24 aryl group, or a C7 to C40 alkylaryl group; and L is a heteroatom or heteroatom-containing group bound to T, Cp is a cyclopentadienyl ring substituted with 0 to 4 substituent groups (where adjacent groups can form C4 to C20 rings); A is Cp or (JS?z*-1-y), where J is a Group 15 or 16 element; S? is a hydrocarbyl, substituted hydrocarbyl, or heteroatom; z* is 2 or 3, and y is 0 or 1, is provided.

Abstract: This invention relates to a process for the preparation of a silica-treated functionalized resin composition comprising the steps of reacting a polymer backbone with a hydrosilylation agent to produce a silane-functionalized resin composition, wherein the polymer backbone is selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof; and mixing the silane-functionalized resin composition with a silica to produce a silica-treated functionalized resin composition.

Abstract: This invention relates to a functionalized resin composition having the formula P—S—X where S is a spacer selected from at least one of C2-C40 straight chain and branched alkyl, C6-C40 aromatics, butadiene, isoprene, and combinations thereof, P is a polymer backbone selected from at least one of dicyclopentadiene (DCPD)-based polymers, cyclopentadiene (CPD)-based polymers, DCPD-styrene copolymers, C5 homopolymers and copolymer resins, C5-styrene copolymer resins, terpene homopolymer or copolymer resins, pinene homopolymer or copolymer resins, C9 homopolymers and copolymer resins, C5/C9 copolymer resins, alpha-methylstyrene homopolymer or copolymer resins, and combinations thereof, and X is a silane.

Abstract: This invention relates to relates to a polyolefin composition comprising one or more of the following formulae: wherein the PO is the residual portion of a vinyl terminated macromonomer (VTM) having had a terminal unsaturated carbon of an allylic chain and a vinyl carbon adjacent to the terminal unsaturated carbon.

Abstract: This invention relates to a reaction product obtained by ring-opening metathesis polymerization of norbornene ketones functionalized with the residual portion of a vinyl terminated macromonomer.

Abstract: An ethylene copolymer, a Group 4 transition metal catalyst compound, and methods for polymerization using such a compound, said compound represented by the formula: (L)p(R?)zT(Cp)(A)MX2, where M is a Group 4 metal; z is 0 to 8; p is 1 to 3; X is an anionic leaving group; T is a bridging group; R1 to R4 are hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group, aryl group, substituted aryl group, or a heteroatom-containing group (where adjacent R groups can form rings); R? is hydrogen, a C1 to C10 alkyl group, a C6 to C24 aryl group, or a C7 to C40 alkylaryl group; and L is a heteroatom or heteroatom-containing group bound to T, Cp is a cyclopentadienyl ring substituted with 0 to 4 substituent groups (where adjacent groups can form C4 to C20 rings); A is Cp or (JS?z*-1-y), where J is a Group 15 or 16 element; S? is a hydrocarbyl, substituted hydrocarbyl, or heteroatom; z* is 2 or 3, and y is 0 or 1, is provided.

Abstract: Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the discovery and evaluation of new therapeutic targets to inhibit metastasis and other markers of carcinogenesis.

Abstract: This invention relates to a reaction product obtained by ring-opening metathesis polymerization of norbornene ketones functionalized with the residual portion of a vinyl terminated macromonomer.

Abstract: Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell. Antibodies against ubiquitin are shown to inhibit tumor cell migration.

Abstract: This invention relates to relates to a polyolefin composition comprising one or more of the following formulae: wherein the PO is the residual portion of a vinyl terminated macromonomer (VTM) having had a terminal unsaturated carbon of an allylic chain and a vinyl carbon adjacent to the terminal unsaturated carbon.

Abstract: Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the discovery and evaluation of new therapeutic targets to inhibit metastasis and other markers of carcinogenesis.

Abstract: Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell. Antibodies against ubiquitin are shown to inhibit tumor cell migration.

Abstract: Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. 1). Antibodies against ubiquitin are shown to inhibit tumor cell migration.

Abstract: Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. 1). Antibodies against ubiquitin are shown to inhibit tumor cell migration.

Abstract: Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.